IP Verse

Crystalline Forms Of An Androgen Receptor Modulator - EP3533792

The patent EP3533792 was granted to Aragon Pharmaceuticals on May 5, 2021. The application was originally filed on Jun 4, 2013 under application number EP19169275A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3533792

ARAGON PHARMACEUTICALS
Application Number
EP19169275A
Filing Date
Jun 4, 2013
Status
Opposition Rejected
Aug 2, 2024
Grant Date
May 5, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKFeb 4, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS12294881
DESCRIPTIONUS12450423
DESCRIPTIONUS5323907
OPPOSITIONWO2007126765
OPPOSITIONWO2008119015
OPPOSITIONWO2013184681
SEARCHWO2007126765
SEARCHWO2008119015
SEARCHWO2011103202

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- J Clin Oncol, (19930000), vol. 11, no. 8, pages 1566 - 72-
DESCRIPTION- Science, (20090508), vol. 324, no. 5928, pages 787 - 790-
OPPOSITION- De Gruyter W., "DIE PRAXIS DES ORGANISCHEN CHEMIKERS", GATTERMANN . WIELAND, (19820000), pages 69 - 77, XP055893934-
OPPOSITION- JOHN BERNSTEIN, "Chapter 1", Polymorphism in Molecular Crystals, Oxford, (20020000), pages 9 - 10, XP055893956-
OPPOSITION- Keith Guillory, "5 Generation of Polymorphs Hydrates, Solvates, and Amorphous Solids", POLYMORPHISM IN PHARMACEUTICAL SOLIDS, M. Dekker, USA, (19990000), vol. 183, page 193, XP055539265-
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- CLEGG et al., "ARN-509: ''A Novel Antiandrogen for Prostate Cancer", Cancer Research, (20120000), vol. 72, no. 6, doi:10.1158/0008-5472.CAN-11-3948, pages 1494 - 1503, XP008166073
OPPOSITION- CLEGG et al., "ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment", Cancer Research, (20120000), vol. 72, no. 6, pages 1494 - 1503, XP008166073
SEARCH- NICOLA J. GREGG, JOHN WONGVIPAT, JAMES D. JOSEPH, CHRIS TRAN, SAMEDY OUK ET AL, "ARN-509: A novel antiandrogen for prostate cancer treatment", CANCER RESEARCH, (20120120), vol. 72, no. 6, doi:10.1158/0008-5472.CAN-11-3948, pages 1494 - 1503, XP002756285 [A] 1-15 * compound ARN-509;; figure 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents